50
Participants
Start Date
April 28, 2025
Primary Completion Date
March 31, 2030
Study Completion Date
March 31, 2030
Glofitamab
Participants will receive IV glofitamab for up to 12 cycles (cycle length = 21 days)
Tocilizumab
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Obinutuzumab
Participants will receive IV obinutuzumab pretreatment
Gemcitabine
Participants will receive IV gemcitabine for up to 8 cycles (cycle length = 21 days)
Oxaliplatin
Participants will receive IV oxaliplatin for up to 8 cycles (cycle length = 21 days)
RECRUITING
Thomas Jefferson University, Philadelphia
RECRUITING
Georgetown University, Washington D.C.
RECRUITING
Walter Reed National Military Medical Center, Bethesda
RECRUITING
Winship Cancer Institute of Emory University, Atlanta
RECRUITING
AdventHealth Cancer Institute, Orlando
RECRUITING
University of Illinois Cancer Center, Chicago
RECRUITING
Kansas City VA Medical Center, Kansas City
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
Renovatio Clinical, The Woodlands
RECRUITING
Renovatio Clinical - El Paso, El Paso
RECRUITING
Christus Health - Christus St. Vincent Regional Medical Center, Santa Fe
RECRUITING
UC San Diego Moores Cancer Center, La Jolla
RECRUITING
Saddleback Memorial Medical Center, Laguna Hills
RECRUITING
University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica
Hoffmann-La Roche
INDUSTRY